Masoud Khayyami, acting CEO of SpectraCure, will present the company at an investor meeting organized by Cardeon in Lund on December 5th.
For further information regarding the event schedule and registration, please visit: https://storage.mfn.se/dd21b2ac-5a14-4b98-addb-0b17de29e758/kapitaldag-info-och-schema.pdf
SpectraCure is developing the future systems for the treatment of internal solid cancer tumours. The goal of the proprietary and patented treatment system is to eliminate deep-seated cancer tumours and prolong the survival of cancer patients while maintaining their quality of life. When prostate cancer recurs, there are often no established treatment options other than lifelong hormone therapy, with its associated side effects.